Financial Performance - The company's revenue for Q3 2025 reached ¥980.24 million, a year-on-year increase of 5.39%[5] - Total profit for the period was ¥234.69 million, reflecting a growth of 5.36% compared to the same period last year[5] - Net profit attributable to shareholders was ¥214.66 million, up 3.02% year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥204.51 million, showing a significant increase of 11.25%[5] - Basic earnings per share for the period were ¥0.36, representing a 2.86% increase compared to the previous year[5] - Total operating revenue for the first three quarters of 2025 reached ¥3,047,039,079.24, a significant increase of 35.8% compared to ¥2,245,006,087.12 in the same period of 2024[24] - Net profit for the first three quarters of 2025 was ¥818,339,617.30, representing a year-over-year growth of 61.3% from ¥507,265,199.52 in 2024[24] - Operating profit increased to ¥868,653,239.12, up 54.3% from ¥562,258,052.99 in the previous year[24] - Basic and diluted earnings per share for the first three quarters of 2025 were both ¥1.38, up from ¥0.85 in the same period of 2024[25] Cash Flow and Assets - The company reported a significant increase in net cash flow from operating activities, totaling ¥481.96 million, up 3.57% year-to-date[5] - Cash flow from operating activities generated a net amount of ¥481,960,456.57, compared to ¥465,340,293.85 in the same period last year[27] - Cash and cash equivalents increased to ¥2,064,233,725.12 from ¥902,777,760.68, representing a growth of 128.0%[22] - Cash and cash equivalents at the end of the period totaled ¥338,956,379.99, an increase from ¥272,242,587.07 at the end of the same period in 2024[27] - Total current assets reached ¥4,968,496,815.27, up from ¥3,790,858,209.05, reflecting a growth of 31.1%[22] - Accounts receivable rose to ¥529,627,542.60 from ¥213,714,496.82, an increase of 148.0%[22] - Total assets of the company at the end of the reporting period were ¥12.14 billion, a slight increase of 0.83% from the end of the previous year[5] Liabilities and Equity - Total liabilities decreased to ¥860,365,215.93 from ¥988,445,729.70, a reduction of 12.9%[23] - Total equity attributable to shareholders increased to ¥11,282,392,471.03 from ¥11,054,470,662.18, a rise of 2.1%[23] Sales Performance - Domestic sales revenue for insulin preparations reached ¥2.69 billion, an increase of ¥822 million, with a growth rate of 44.01%[13] - International sales revenue amounted to ¥353 million, up ¥110 million, reflecting a growth of 45.52%[15] Investments and Agreements - The company signed a 10-year supply framework agreement with Brazilian partners, with a total order value expected to exceed ¥3 billion[15] - The company’s long-term investments in non-current financial assets rose to ¥72,190,190.44 from ¥11,713,152.96, an increase of 516.5%[22] Shareholder Information - Total number of common shareholders at the end of the reporting period is 94,714[19] - The number of shares held by the largest shareholder, Gan Zhongru, is 205,643,757, representing 34.42% of total shares[19] - The company has no significant changes in the participation of major shareholders in margin trading and securities lending[20] Research and Development - Research and development expenses for the first three quarters of 2025 were ¥407,861,819.05, slightly up from ¥403,442,931.89 in 2024, indicating continued investment in innovation[24] Operating Costs - The total operating costs for the first three quarters of 2025 were ¥2,275,937,092.07, an increase of 18.5% from ¥1,921,772,067.24 in 2024[24] Comprehensive Income - The company reported a total comprehensive income of ¥817,932,852.54 for the first three quarters of 2025, compared to ¥506,399,943.50 in 2024[25]

从资金流向上来看，当日生物制品板块主力资金净流出3.45亿元，游资资金净流入6848.58万元，散户资 金净流入2.77亿元。生物制品板块个股资金流向见下表： 证券之星消息，10月27日生物制品板块较上一交易日上涨0.33%，智翔金泰领涨。当日上证指数报收于 3996.94，上涨1.18%。深证成指报收于13489.4，上涨1.51%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688443 | 智别全泰 | 30.11 | 6.58% | 8.74万 | 2.61亿 | | 688331 | 荣昌生物 | 93.79 | 4.00% | 6.77万 | 6.37亿 | | 603087 | 甘李药业 | 71.52 | 3.91% | 12.97万 | 9.21亿 | | 301047 | 义翘神州 | 75.03 | 3.65% | 1.94万 | 1.44亿 | | 688105 | 诺唯赞 | 23.19 | 3.25% | 3.91万 | 9031.5 ...

证券代码：603087 证券简称：甘李药业 公告编号：2025-069 甘李药业股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司将于 2025 年 10 月 31 日在上海证券交易所网站（www.sse.com.cn）披 露《2025 年第三季度报告》。为便于广大投资者更全面深入地了解公司状况，公 司决定于 2025 年 11 月 3 日上午 9:00-10:00 举行 2025 年第三季度业绩说明会， 对公司的经营成果及财务指标的具体情况进行充分交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第三季度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 会议召开时间：2025 年 11 月 3 日（星期一）9:00-10:00 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.sse ...

Core Insights - The Chinese innovative pharmaceutical industry is accelerating its "going global" process, with significant business development (BD) transactions occurring in October, including a record $11.4 billion deal between Innovent Biologics and Takeda Pharmaceutical [1][2][3] Group 1: Major Transactions - Innovent Biologics announced a global strategic collaboration with Takeda Pharmaceutical, integrating their strengths in tumor immunology and antibody-drug conjugates (ADC), with a total deal value of up to $11.4 billion [1] - The agreement includes an upfront payment of $1.2 billion, which consists of a $1 billion premium strategic equity investment, along with potential milestone payments and future sales revenue sharing [1] - Other companies, such as Hansoh Pharmaceutical and Beijing Ausun Pharmaceutical, have also reported significant BD agreements, indicating a strong market interest in Chinese innovative drugs [2] Group 2: Market Trends - The Chinese innovative drug sector is becoming a major player in global pharmaceutical BD activities, with a notable increase in overseas licensing transactions in 2023 [2][3] - The current trend shows that the majority of Chinese innovative drugs are entering international markets through BD licensing rather than independent market entry due to the high costs and risks associated with the latter [3] - The surge in BD transactions is attributed to the rapid advancements of Chinese companies in emerging fields like ADCs and cell therapies, as well as the need for multinational pharmaceutical companies to fill revenue gaps from expiring patents [3]

Group 1 - The core point of the article highlights the acceleration of Chinese innovative drug companies' international expansion, marked by significant business development (BD) transactions, including a record $11.4 billion deal between Innovent Biologics and Takeda Pharmaceutical [1][3] - Innovent Biologics announced a global strategic collaboration with Takeda, integrating their strengths in immuno-oncology and antibody-drug conjugates to expedite the global development of two late-stage drugs, with an upfront payment of $1.2 billion and potential milestone payments [1] - Other Chinese pharmaceutical companies, such as Hansoh Pharmaceutical and Beijing Ausun Pharmaceutical, have also reported significant BD agreements, indicating sustained market interest and high premium recognition for domestic innovative drugs [2] Group 2 - Chinese innovative pharmaceutical companies have significantly improved their R&D capabilities, becoming one of the most active forces in global BD, with a notable increase in overseas licensing transactions in 2023 [3] - The current trend of "going global" for innovative drugs primarily involves two models: self-driven internationalization and BD partnerships, with the latter being favored due to lower costs and risks [3] - The surge in BD activities in October is seen as a reflection of Chinese innovative drug companies entering the global mainstream, as multinational pharmaceutical companies seek to fill revenue gaps from patent expirations by collaborating with Chinese firms [4]

Market Overview - The biopharmaceutical sector experienced a decline of 0.57% on October 22, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Wendi Pharmaceutical (688488) with a closing price of 14.77, up 4.01% [1] - Dongbao Bio (300239) at 5.78, up 2.66% [1] - Jinke (688670) at 17.03, up 2.59% [1] - Major decliners included: - Aopumai (688293) at 55.19, down 4.40% [2] - Wofu Bio (300357) at 31.63, down 3.18% [2] - Sanofi (688336) at 59.60, down 2.39% [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 192 million yuan from institutional investors, while retail investors contributed a net inflow of 53.82 million yuan [2] - Specific stock capital flows included: - Te Bao Bio (688278) with a net inflow of 19.00 million yuan from institutional investors [3] - Hualan Bio (002007) with a net inflow of 12.05 million yuan from institutional investors [3] - Aopumai (688293) with a net outflow of 4.40% from institutional investors [3]

Core Points - Beijing Xute Hongda Technology Co., Ltd. holds 32,073,734 shares of Ganli Pharmaceutical Co., Ltd., accounting for 5.37% of the total share capital. Recently, Xute Hongda completed the release of 600,000 shares from pledge, reducing the total pledged shares to 23,410,000, which is 72.99% of its holdings and 3.92% of the total share capital [1] - The controlling shareholder, Mr. Gan Zhongru, and Xute Hongda together hold 237,717,491 shares, representing 39.80% of the total share capital. After the release of the pledge, the total pledged shares amount to 23,410,000, which is 9.85% of their holdings and 3.92% of the total share capital [1] Pledge Release Situation - The announcement details the situation regarding the release of share pledges by the shareholders [1] Cumulative Pledged Shares Situation - As of the announcement date, the cumulative pledged shares by the shareholders and their concerted actions are outlined [1] Impact of Pledged Shares on the Company - The 5% shareholder, Xute Hongda, has a good credit status and sufficient repayment capability. The pledged shares currently do not pose a risk of forced liquidation or transfer, indicating that the pledge risk is manageable and will not materially affect the company's operations [1]

Group 1 - The core point of the announcement is that Beijing Xutong Hongda Technology Co., Ltd. has completed the release of 600,000 shares of Ganli Pharmaceutical, reducing its pledged shares to 23,410,000, which is 72.99% of its holdings [1][2] - After the release of the pledge, the total shares held by the controlling shareholder and actual controller, Mr. Gan Zhongru, and Xutong Hongda is 237,717,491 shares, accounting for 39.80% of the total share capital [1][2] - The company states that the financial condition of the 5% shareholder, Xutong Hongda, is good, and there are no risks of forced liquidation or transfer of pledged shares, indicating that the pledge risk is under control and will not materially affect the company's operations [2] Group 2 - As of the announcement date, the cumulative pledged shares of the aforementioned shareholders and their concerted actions are detailed, showing the extent of share pledges [2] - The company will continue to monitor the stock pledge situation and risks of the 5% shareholder, Xutong Hongda, and will disclose relevant information in a timely manner according to regulations [2]

Core Points - Gannee Pharmaceutical announced that Beijing Xute Hongda Technology Co., Ltd. holds 32,073,734 shares of the company, accounting for 5.37% of the total share capital [1] - On October 20, 2025, the company received notification that Xute Hongda has completed the release registration procedures for 600,000 shares [1] - After the release of the pledge, Xute Hongda has pledged a total of 23,410,000 shares, which is 72.99% of its holdings and 3.92% of the company's total share capital [1]

北京旭特宏达科技有限公司（以下称"旭特宏达"）持有甘李药业股份 有限公司（以下简称"公司"）无限售条件流通股 32,073,734 股，占公司总股本 的 5.37%。2025 年 10 月 20 日公司收到通知，旭特宏达已于近日办理完毕 600,000 股公司股份的解押登记手续。本次股份解除质押后，旭特宏达累计质押公司股份 数量为 23,410,000 股，占其持股数量的 72.99%，占公司总股本的 3.92%。 控股股东、实际控制人甘忠如先生及其控制的北京旭特宏达科技有限公 司（以下简称"旭特宏达"）合计持有公司股份 237,717,491 股，占公司总股本 的 39.80%。本次股份解除质押后，甘忠如先生及旭特宏达累计质押公司股份数 量为 23,410,000 股，占其持股数量的 9.85%，占公司总股本的 3.92%。 | 股东名称 | 旭特宏达 | | | | --- | --- | --- | --- | | 本次解除质押股份 | 股 600,000 | | | | 占其所持股份比例 | 1.87% | | | | 占公司总股本比例 | 0.10% | | | | 解除质押/冻结/标记时间 | 年 ...